Figure 5.
Randomized, double-blind, placebo-controlled study of single ascending oral doses of IOA-289. Healthy male volunteers were administered a single dose of IOA-289 in a capsule formulation (six active subjects per cohort, placebo not analyzed), at increasing dose levels. Plasma exposure of IOA-289 was measured up to 24 h after dose (A). LPA C18:2 in plasma was measured at baseline and up to 24 h after dose; data are % inhibition of baseline levels (B). Using the pharmacokinetic and pharmacodynamic data, the IC50 of IOA-289 was calculated as 15 ng/ml in human plasma (C).
LPA, lysophosphatidic acid.